Table 1.
Characteristics of the 5,249 patients
| Variable | Median (range) |
|---|---|
| Age, yr | 71 (22–98) |
| Gender, male, % | 3,662 (69.6) |
| Etiology B/C/BC/NBNC, % | 678 (12.9)/3,083 (58.6)/25 (0.5)/1,473 (28.0) |
| Plt, ×104/µL | 12.6 (1.2–98.0) |
| PT, % | 83.0 (7.3–143.0) |
| Alb, g/dL | 3.70 (1.30–7.40) |
| T.Bil, mg/dL | 0.80 (0.10–43.40) |
| AFP, ng/mL | 15.20 (0.30–1,454,000.0) |
| PIVKA-II, mAU/mL | 65.0 (0.00–3,000,000.0) |
| Child-pugh A/B/C, % | 3,751 (71.3)/1,249 (23.7)/259 (4.9) |
| TNM staging I/II/III/IV, % | 1,314 (25.0)/2,076 (39.5)/1,137 (21.6)/732 (13.9) |
| ALBI grade 1/2/3, % | 1,837 (36.2)/2,856 (56.3)/378 (7.5) |
| JIS grade 0/1/2/3/4/5, % | 976 (19.2)/1,780 (35.1)/1,181 (23.3)/740 (14.6)/297 (5.9)/97 (1.9) |
| ALBI-T grade 0/1/2/3/4/5, % | 501 (9.9)/1,564 (30.8)/1,410 (27.8)/935 (18.4)/535 (10.6)/126 (2.5) |
| Treatment: Resection/RFA/TACE/others/BSC, % | 1,328 (25.3)/1,969 (37.4)/1,223 (23.3)/210 (4.0)/529 (10.1) |
Plt, platelet; PT, prothrombin; Alb, albumin; T.Bil, total bilirubin; AFP, alfa-feto protein; PIVKA-II, protein induced by vitamin K absence or antagonist-II; TNM staging, tumor, node, and metastasis staging for HCC, was determined based on the 6th edition of “The General Rules for the Clinical and Pathological Study of Primary Liver Cancer” developed by the Liver Cancer Study Group of Japan (LCSGJ); JIS, Japan Integrated Score; RFA, radiofrequency ablation; TACE, transarterial chemoembolization; BSC, best supportive care.